NCT04076787View on ClinicalTrials.gov

Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib

CompletedOBSERVATIONAL

Enrollment

1,769

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

September 2, 2018

Study Completion Date

September 2, 2018

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG

Sunitinib

patients who received sunitinib as first line therapy for mRCC

Trial Locations (1)

P2N4N2

University of Calgary, Calgary

Sponsors

Lead Sponsor

Collaborators (1)

Analysis Group, Inc.

All Listed Sponsors

collaborator

International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)

OTHER

collaborator

Analysis Group, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY